Adrenal Tumors - Pathogenesis and Therapy

Pheochromocytoma Clinical Trial

Official title:

Investigation of the Tumorigenesis of Adrenal Tumors and Evaluation of New Therapeutic Options - Untersuchungen Zur Tumorgenese Von Nebennierentumoren Und Evaluation Neuer Therapieoptionen

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT00669266
• Other study ID #: Wue-Adrenal-Tumors-92/2002
• Status: Recruiting
• Start date: September 2002
• Est. completion date: December 2030

Study information

• Verified date: April 2024
• Source: University of Wuerzburg
• Contact: Martin Fassnacht, MD
• Phone: 49-931-201-36507
• Email: fassnacht_m[@]medizin.uni-wuerzburg.de
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The pathogenesis of adrenal tumors is still not fully elucidated and the treatment options for malignant tumors are poor. The current study investigates different aspects of the pathogenesis of adrenal tumors and evaluates different therapeutic options in patients with adrenocortical carcinoma.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 500
• Est. completion date: December 2030
• Est. primary completion date: December 2030
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 100 Years

Eligibility

Inclusion Criteria:

• adrenal tumor detected by imaging

Exclusion Criteria:

Related Conditions & MeSH terms

• Adrenal Gland Neoplasms
• Adrenal Tumors
• Adrenocortical Carcinoma
• Conn Syndrome
• Cushing Syndrome
• Hyperaldosteronism
• Pheochromocytoma
• Syndrome

Locations

Country	Name	City	State
Germany	University of Wuerzburg	Wuerzburg

Sponsors (3)

Lead Sponsor	Collaborator
University of Wuerzburg	Deutsche Krebshilfe e.V., Bonn (Germany), German Federal Ministry of Education and Research

Country where clinical trial is conducted

Germany, 

References & Publications (6)

Beuschlein F, Fassnacht M, Assie G, Calebiro D, Stratakis CA, Osswald A, Ronchi CL, Wieland T, Sbiera S, Faucz FR, Schaak K, Schmittfull A, Schwarzmayr T, Barreau O, Vezzosi D, Rizk-Rabin M, Zabel U, Szarek E, Salpea P, Forlino A, Vetro A, Zuffardi O, Kis — View Citation

Ronchi CL, Di Dalmazi G, Faillot S, Sbiera S, Assie G, Weigand I, Calebiro D, Schwarzmayr T, Appenzeller S, Rubin B, Waldmann J, Scaroni C, Bartsch DK, Mantero F, Mannelli M, Kastelan D, Chiodini I, Bertherat J, Reincke M, Strom TM, Fassnacht M, Beuschlei — View Citation

Sbiera I, Kircher S, Altieri B, Lenz K, Hantel C, Fassnacht M, Sbiera S, Kroiss M. Role of FGF Receptors and Their Pathways in Adrenocortical Tumors and Possible Therapeutic Implications. Front Endocrinol (Lausanne). 2021 Dec 9;12:795116. doi: 10.3389/fen — View Citation

Tamburello M, Altieri B, Sbiera I, Sigala S, Berruti A, Fassnacht M, Sbiera S. FGF/FGFR signaling in adrenocortical development and tumorigenesis: novel potential therapeutic targets in adrenocortical carcinoma. Endocrine. 2022 Sep;77(3):411-418. doi: 10. — View Citation

Weigand I, Ronchi CL, Vanselow JT, Bathon K, Lenz K, Herterich S, Schlosser A, Kroiss M, Fassnacht M, Calebiro D, Sbiera S. PKA Calpha subunit mutation triggers caspase-dependent RIIbeta subunit degradation via Ser114 phosphorylation. Sci Adv. 2021 Feb 19 — View Citation

Weigand I, Schreiner J, Rohrig F, Sun N, Landwehr LS, Urlaub H, Kendl S, Kiseljak-Vassiliades K, Wierman ME, Angeli JPF, Walch A, Sbiera S, Fassnacht M, Kroiss M. Active steroid hormone synthesis renders adrenocortical cells highly susceptible to type II — View Citation